Zoetis Inc., formerly the animal health business unit of Pfizer Inc., announced plans July 2 to expand its manufacturing facility in Lincoln, Neb., to facilitate the production of high-quality, reliable medicines for veterinarians, livestock producers and the animals under their care.
Zoetis said it expects this expansion to affirm its longstanding commitment to being a world-class manufacturer of animal health products as well as to continue to be an employer of choice in Lincoln.
The plan calls for a 19,000 sq. ft., three-story expansion of the existing production facility to accommodate the transfer of products from a third-party manufacturer to Lincoln. Early stages of planning and construction have begun and groundbreaking is expected to occur later this summer, initiating the start of the full construction phase. Zoetis expects to complete construction in 2014.
This expansion will help ensure a reliable, consistent supply of medicines for animals, the announcement said. Today, Zoetis produces some of its flagship pharmaceutical products and vaccines at the Lincoln plant, including Bovi-Shield Gold and RespiSure One for livestock and Rimadyl for dogs.
The site is one of the largest internal manufacturing operations within Zoetis, employing more than 500 people today; the facility expansion could create as many as 30 new positions at peak production time.